ID
37132
Description
Study ID: 104864/502 Clinical Study ID: 104864/502 Study Title: An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: N/A Study Indication: Cancer, Locally Advanced or Metastatic Cervical Cancer
Keywords
Versions (1)
- 7/3/19 7/3/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 3, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Oral Topotecan Daily x 5 Days vs. Oral Topotacan 5 Days On, 2 Days Off; 104864/502
Patient Log
- StudyEvent: ODM
Description
Patient Log
Alias
- UMLS CUI-1
- C0030705
- UMLS CUI-2
- C1708728
Description
Investigator Name
Data type
text
Alias
- UMLS CUI [1]
- C2826892
Description
Person Initials
Data type
text
Alias
- UMLS CUI [1]
- C2986440
Description
Interview, Date in time
Data type
date
Alias
- UMLS CUI [1,1]
- C0021822
- UMLS CUI [1,2]
- C0011008
Description
Exclusion, Reason and Justification
Data type
text
Alias
- UMLS CUI [1,1]
- C2828389
- UMLS CUI [1,2]
- C0566251
Similar models
Patient Log
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])